Han, K.K., Soares Jr., J.M., Haidar, M.A., de Lima, G.R. and Baracat, E.C. (2002) Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstetrics & Gynecology, 99, 389-394. http://dx.doi.org/10.1016/S0029-7844(01)01744-6

has been cited by the following article:

• TITLE: Effect of daily supplementation of soy isoflavones on hot flashes and night sweats in African menopausal women

  AUTHORS: Ronbinson Enow Mbu, Yao Raphaël Abauleth, Akpadza Koffi, Namory Keita, Amadou Dolo, Jean Lankoande

  KEYWORDS: Menopause; Climacteric Disorders; Hot Flashes; Night Sweats; Soy Isoflavones; Genistin, Daidzin; Genistein; Daidzein; Inoclim

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.4 No.1, January 16, 2014

  ABSTRACT: The aim of this study was to evaluate the effectiveness of a pharmaceutical grade isoflavone supplement (Inoclim?) 40 mg per capsule of soy extract rich in daidzin and genistin) on the number of hot flashes and night sweats in menopausal African women. This open, prospective, multicenter study involved 140 menopausal women with climacteric symptoms (i.e., a minimum of five hot flashes and/or moderate to severe night sweats per day). These patients received a daily 40-mg supplement of soy isoflavone contained in an Inoclim? capsule (Laboratoire Innotech International, France). The dose was increased to two capsules per day when there were more than five hot flashes or when the women could not sleep because of night sweats. The patients were followed up over a 4-month period and data were analyzed using EPI-InfoTM version 3.5.1. The outcome measure was fewer hot flashes and night sweats. The mean daily number of episodes of hot flashes was 5.7 at baseline and 1.8 at week 16, corresponding to a decrease of 68.4% (n = 93 patients at baseline and n = 66 at 16 weeks). The mean number of daily episodes of night sweats was 3.7 at baseline and 0.8 at week 16, corresponding to a decrease of 78.4% (n = 127 patients in the first week and n = 73 at 16 weeks). Over 80% of patients took a single one 40 mg capsule per day. The percentage of patients who adhered to the prescription was more than 95% during the 4-month follow-up period. These results confirm the effectiveness of a pharmaceutical grade isoflavone supplement (40 mg, rich in genistin and daidzin) on vasomotor symptoms in menopausal women.